Improving the Identification of Disease Modification PD Targets and Their Testing in Clinical Trials

November 21, 2019 - November 22, 2019

Contact: Carlos Faraco
Contact Email: carlos.faraco@nih.gov
Location:

NSC
Conference Room C
6001 Executive Blvd.
Rockville, MD 20852

 


 

Image
Improving the Identification of Disease Modification PD Targets and Their Testing in Clinical Trials flyer

This workshop brought together leaders in the field and a wide range of stakeholders, to discuss the challenges and gaps in disease modification therapy for Parkinson’s. For more than 3 decades, efforts to achieve this goal have fallen short, in spite of ever improving basic science rigor and trial design. NINDS lead and assessment of the needs and identification of solutions and priorities. The workshop included participants from academia, industry, private foundations, and government organizations. The history of disease modification attempts was discussed, and discussions of the preliminary data requirements, trial designs, and research priorities were included. Participants from other fields shared their experience and vision. An important focus was to harmonize efforts and utilize potential synergies, both among funding organizations and researchers studying similar topics.

Related Resources

Agenda(pdf, 199 KB)

Following this workshop with experts from industry, academia, and the nonprofit sector, NINDS facilitated the drafting of a review paper with workshop participants. Using the key discussion topics as a starting point, this paper discusses the history, major barriers to progress, and future directions for disease modifying therapies for Parkinson's disease.

Interested parties may access the paper via PubMed.gov: Seeking progress in disease modification in Parkinson disease